Advertisement

ASCO 2022: Asciminib vs Bosutinib in Pretreated Patients With CML in Chronic Phase
Posted: 07/19/2022 | By: Justine Landin, PhD

At the 2022 ASCO Annual Meeting, Rea et al presented efficacy and safety results from the phase III ASCEMBL study, which compared asciminib to bosutinib in patients diagnosed with chronic myeloid leukemia (CML) in chronic phase who had been pretreated with tyrosine kinase inhibitors.

Question 1 of 5

Which of the following is FALSE regarding asciminib vs bosutinib treatment?

Choose 1

A
Patients treated with asciminib had a longer duration of treatment
B
Bosutinib treatment resulted in fewer adverse events of grade 3 or higher
C
BCR::ABL1IS of 1% or less was higher in patients who received asciminib
D
The probability of maintaining major molecular response for 72 weeks or more was greater than 90% for both groups

CategoriesView All Quizzes

Tumor Type


Additional Topics



Conference Coverage